Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CEO Lindsay A. Md Rosenwald purchased 763,359 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was purchased at an average cost of $1.84 per share, for a total transaction of $1,404,580.56. Following the acquisition, the chief executive officer now owns 3,657,264 shares in the company, valued at $6,729,365.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Fortress Biotech Price Performance
NASDAQ:FBIO traded up $0.02 during mid-day trading on Wednesday, hitting $1.41. 1,048,424 shares of the company’s stock were exchanged, compared to its average volume of 342,561. Fortress Biotech, Inc. has a one year low of $1.24 and a one year high of $5.25. The company has a current ratio of 1.37, a quick ratio of 1.24 and a debt-to-equity ratio of 38.42. The business has a fifty day moving average price of $1.96 and a 200 day moving average price of $1.88.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.59. The business had revenue of $14.90 million for the quarter, compared to the consensus estimate of $14.97 million. On average, sell-side analysts anticipate that Fortress Biotech, Inc. will post -2.65 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on Fortress Biotech
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of FBIO. Armistice Capital LLC purchased a new position in Fortress Biotech in the fourth quarter worth about $1,794,000. Acadian Asset Management LLC raised its holdings in Fortress Biotech by 124.3% in the first quarter. Acadian Asset Management LLC now owns 292,058 shares of the biopharmaceutical company’s stock worth $582,000 after buying an additional 161,870 shares during the last quarter. PVG Asset Management Corp purchased a new position in Fortress Biotech in the second quarter worth about $266,000. B. Riley Wealth Advisors Inc. purchased a new position in Fortress Biotech in the second quarter worth about $207,000. Finally, 180 Wealth Advisors LLC purchased a new position in Fortress Biotech in the second quarter worth about $107,000. 96.51% of the stock is owned by hedge funds and other institutional investors.
About Fortress Biotech
Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.
Featured Articles
- Five stocks we like better than Fortress Biotech
- Differences Between Momentum Investing and Long Term Investing
- Should You Invest in Treasury Bills?
- Why Are Stock Sectors Important to Successful Investing?
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- What to Know About Investing in Penny Stocks
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.